ABSTRACT:
The human endogenous intestinal microflora is an essential “Organ” in providing nourishment, regulating epithelial development and instructing innate immunity. This flora is a positive health assest that crucially influences the normal structural and functional development of mucosal immune system. In genetically susceptible individuals, some components of flora can become a liability and contribute to the pathogenesis of various intestinal disorders including inflammatory bowel diseases (IBDS). Therefore, it is understood that manipulation of the flora to enhance the beneficial component and simultaneous treatment of prevailing inflammation of colon with colon specific antiinflammatory agent represents a promising therapeutic strategy. Hence, a probiotic gel containing combination of selected Lactobacillus species with Mesalazine, a golden standard antiinflammatory agent for treatment of colitis was formulated and characterized for its in vitro performance. This gel is expected to act locally on the left side colitis, which is the most common symptom of IBDS including ulcerative colitis.